Evidence map›Paper›PMID 35098436›Full record

ArticleAnnals of nuclear medicine2022

[

Kazuo Kubota, Toshiyuki Saginoya, Kiichi Ishiwata, Tatsuhiko Nakasato, Hirotsugu Munechika

Open access · bronzeAbstract read
In one paragraph

Article in Annals of nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kazuo KubotaDepartment of Radiology, Southern TOHOKU General Hospital, 7-115 Yatsuyamada, Koriyama City, Fukushima, 963-8563, Japan. kkubota@cpost.plala.or.jp.ORCID http://orcid.org/0000-0001-9637-2834
Toshiyuki SaginoyaDepartment of Radiology, Southern TOHOKU General Hospital, 7-115 Yatsuyamada, Koriyama City, Fukushima, 963-8563, Japan.
Kiichi IshiwataDepartment of Radiology, Southern TOHOKU General Hospital, 7-115 Yatsuyamada, Koriyama City, Fukushima, 963-8563, Japan.
Tatsuhiko NakasatoDepartment of Radiology, Southern TOHOKU General Hospital, 7-115 Yatsuyamada, Koriyama City, Fukushima, 963-8563, Japan.
Hirotsugu MunechikaDepartment of Radiology, Southern TOHOKU General Hospital, 7-115 Yatsuyamada, Koriyama City, Fukushima, 963-8563, Japan.
Southern Tohoku General Hospital · JPFukushima Medical University · JP

Funding

Japan Society for the Promotion of Science JP19H03608
6 · The paper itself

Abstract

purposeReactive FDG uptake in the axillary lymph nodes (ALN) and deltoid muscle (DM) after COVID-19 mRNA vaccination has been recognized, although the actual situation in the Japanese population remains unknown. To determine the incidence of reactive FDG uptake and its contributing factors, we retrospectively studied a cohort of subjects who were vaccinated at our hospital.

methodsWhole-body FDG-PET/CT examinations performed in 237 subjects out of 240 subjects with a definite history of COVID-19 vaccination (BNT162b2; BioNTech-Pfizer) were analyzed. Positivity and SUVmax of FDG uptake in the ALN and DM ipsilateral to vaccination, various subject characteristics, and the grade of the pathological FDG-PET/CT findings were evaluated using a multivariate analysis.

resultsFDG uptake in the ALN and DM ipsilateral to vaccination was seen in about 60% of the subjects even soon (0-4 days) after the first vaccination, with percentages reaching 87.5% and 75.0%, respectively, after the second vaccination. DM uptake had almost disappeared at around 2 weeks, while ALN uptake persisted for 3 weeks or longer. A multivariate analysis showed that a short duration since vaccination, a younger age, a female sex, and a low FDG-PET/CT grade (minimal pathological FDG uptake) contributed significantly to positive ALN uptake, while a short duration since vaccination and a female sex were the only significant contributors to positive DM uptake. This study is the first to identify factors contributing to positive FDG uptake in ALN and DM after COVID-19 vaccination.

conclusionA high incidence of FDG uptake in ALN and DM was observed after vaccination. ALN uptake seemed to be associated with a younger age, a female sex, and minimal pathological FDG uptake. After vaccination, an acute inflammatory reaction in DM followed by immune reaction in ALN linked to humoral immunity may be speculated.

Indexed as

Breast NeoplasmsCOVID-19BNT162 VaccineCohort StudiesCOVID-19 VaccinesDeltoid MuscleFemaleFluorodeoxyglucose F18HumansIncidenceLymph NodesMultivariate AnalysisPositron Emission Tomography Computed TomographyRetrospective StudiesRNA, MessengerVaccinationBNT162 VaccineCOVID-19 VaccinesFluorodeoxyglucose F18RNA, MessengerAxillary lymph nodeCOVID-19Deltoid muscleFDGmRNA vaccinePET/CT

Identifiers

PMID35098436
PMCPMC8801267
OpenAlexW4210446665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.